On Health Policy Archives

Comment On Medwatch: The FDA Medical Products Reporting Program

April 23, 2003. Rather than weaken or dismantling the MedWatch system, the FDA should borrow ideas from more rigorous systems in other countries. The FDA should provide ongoing education and incentives for quality reporting by both health professionals and consumers.

Comment on FDA Guidance For Industry Collection of Race and Ethnicity Data in Clinical Trials

March 25, 2003. It is the policy of the National Institute of Health that women and members of minority groups must be included in all NIH supported biomedical and behavioral research projects.